🇺🇸 FDA

Company profile · Sponsor

Atrium

Atrium Therapeutics

RNA · NYSE pharma SAN DIEGO, CA, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Atrium (RNA) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker RNA
Exchange NYSE
Company type pharma
Headquarters SAN DIEGO, CA, USA
SEC CIK 0002093101

Pipeline (24)

Search pipeline →

  1. PGET

    Atrium

    Osteoarthritis

    phase 3 other terminated

    1 trial

  2. Phlebotomy

    Atrium

    Hemochromatosis

    phase 3 other completed

    1 trial

  3. Phlebotomy and erythrocytapheresis

    Atrium

    Hereditary Hemochromatosis

    phase 3 other active

    1 trial

  4. Ropivacaine HCL

    Atrium

    Renal Carcinoma

    phase 3 small molecule active

    1 trial

  5. Wobenzym® N

    Atrium

    Knee Osteoarthritis

    phase 3 other terminated

    1 trial

  6. eythrocytapheresis

    Atrium

    Pre Operative Autologous Donation

    phase 3 other completed

    1 trial

  7. Carboplatin

    Atrium

    Lung Cancer Stage II

    phase 2 small molecule active

    1 trial

  8. Diclofenac

    Atrium

    Wobenzym

    phase 2 small molecule completed

    1 trial

  9. Elotuzumab

    Atrium

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  10. Low-dose ASA

    Atrium

    Germ Cell Tumor

    phase 2 small molecule active

    1 trial

  11. Metformin Hydrochloride ER

    Atrium

    Sarcoma Metastatic

    phase 2 small molecule active

    1 trial

  12. Nivolumab

    Atrium

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  13. Olutasidenib

    Atrium

    IDH1 Mutation

    phase 2 small molecule active

    1 trial

  14. Vaccine

    Atrium

    Pediatric Cancer

    phase 2 mab active

    1 trial

  15. anastrozole

    Atrium

    Female Breast Carcinoma

    phase 2 small molecule active

    1 trial

  16. IVAC MUTANOME, RBL001/RBL002

    Atrium

    Melanoma

    phase 1 mab completed

    1 trial

  17. Nivolumab

    Atrium

    Brain and Nervous System

    phase 1 small molecule completed

    1 trial

  18. Novel Supplement Based Therapy

    Atrium

    Small Intestinal Bacterial Overgrowth

    phase 1 other terminated

    1 trial

  19. RBL001/RBL002

    Atrium

    Melanoma

    phase 1 mab completed

    1 trial

  20. SAR441000

    Atrium

    Metastatic Neoplasm

    phase 1 small molecule terminated

    1 trial

  21. Phenoxybenzamine

    Atrium

    Pheochromocytoma

    approved small molecule completed

    1 trial

  22. Rivastigmine

    Atrium

    Parkinson's Disease

    approved small molecule terminated

    1 trial

  23. Abciximab local infusion

    Atrium

    Acute Anterior Myocardial Infarction

    small molecule completed

    1 trial

  24. Cranberry

    Atrium

    Endotoxemia

    other completed

    1 trial

Patents (8)

Search patents →

  1. US 11793912

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11166929

    Fatty-acid based particles

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11097035

    Compositions and methods for altering the rate of hydrolysis of cured oil-based materials

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11083823

    Tissue-separating fatty acid adhesion barrier

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10888617

    Cured oil-hydrogel biomaterial compositions for controlled drug delivery

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10869902

    Cured gel and method of making

    Expires Mon Dec 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10864304

    Anti-infective antimicrobial-containing biomaterials

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10814043

    Cross-linked fatty acid-based biomaterials

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Atrium?

Atrium (RNA) is a pharma company. headquartered in SAN DIEGO, CA, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Atrium sponsor?

We track 24 ClinicalTrials.gov-linked programs for Atrium, including PGET and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Atrium company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.